Invasive Fungal Infections– Epidemiology Forecast – 2034
Description
Key Highlights
The global burden of invasive fungal infections has continued to rise in line with the expanding population at risk. In the United States, the burden is estimated at approximately 110,000 cases in 2024 and is projected to increase during the forecast period (2025–2034).
IFIs primarily affect immunocompromised patients, including those with cancer, HIV/AIDS, organ transplants, critical illness, systemic glucocorticoid use, respiratory conditions, or other severe underlying diseases
The analysis covers major invasive fungal infections such as aspergillosis, candidiasis, histoplasmosis, blastomycosis, coccidioidomycosis, cryptococcosis, mucormycosis, and fusariosis, along with other specified and unspecified IFIs, representing the core spectrum of clinical and market relevance.
Despite confirmed diagnoses, case-fatality rates often exceed 30–50%, with many patients dying before treatment begins, highlighting a critical gap in timely intervention.
DelveInsight's “Invasive Fungal Infections– Epidemiology Forecast – 2034” report delivers an in-depth understanding of Invasive Fungal Infections (IFIs), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Invasive Fungal Infections Understanding
Invasive Fungal Infections Overview
Invasive fungal infections, are severe conditions characterized by the invasion of fungal pathogens into normally sterile sites, including deep tissues and vital organs, often leading to prolonged illness and life-threatening complications. They predominantly affect individuals with weakened immunity, such as patients undergoing chemotherapy, individuals with Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or organ transplant recipients receiving immunosuppressive therapy. Invasive fungal infections are most commonly caused by Candida species (especially Candida albicans, C. glabrata, C. tropicalis, among others), Aspergillus species (especially Aspergillus fumigatus), Cryptococcus species, dimorphic fungi and many more. The fungi involved are usually opportunistic pathogens that are part of the environment or normal human flora but become pathogenic when host defenses are impaired.
Invasive Fungal Infections Diagnosis
The diagnosis of invasive fungal infections relies on a combination of laboratory, imaging, and histopathological approaches, as no single method is sufficiently sensitive or specific on its own. Traditional fungal culture remains the gold standard for species identification and susceptibility testing, though it is time-consuming. Rapid diagnostic tools such as antigen detection assays (e.g., galactomannan and ß-D-glucan) and molecular methods (PCR) are increasingly used for early detection and species-level identification, particularly in immunocompromised patients. Imaging modalities like high-resolution CT and MRI are critical for identifying pulmonary and systemic involvement, while direct microscopy and histopathology provide quick, though less sensitive, evidence of fungal presence in tissue or fluids.
Further details related to country-based variations in diagnosis are provided in the report
Invasive Fungal Infections Epidemiology
The IFIs epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total incident cases of invasive fungal infections, total incident cases of invasive fungal infections by type, total treatment-eligible cases of invasive fungal infections, and total refractory cases of invasive fungal infections, in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
Invasive candidiasis and aspergillosis form the largest group of opportunistic invasive fungal infections, primarily affecting immunocompromised populations, together contributing around 50% of the total burden.
Histoplasmosis and coccidioidomycosis together represent a major portion of the endemic pool. Histoplasmosis cases have been steadily rising.
Approximately, 90% of patients develop resistance to first-line antifungal therapy, necessitating therapy modification. Among these, nearly 30% also develop resistance to second-line agents, forcing switches within drug classes (e.g., azoles) or across classes (e.g., from azoles to echinocandins or polyenes).
Invasive Fungal Infections Report Insights
Invasive Fungal Infections Report Insights
Patient population
Country-wise epidemiology distribution
Invasive Fungal Infections Report Key Strengths
Ten-year Forecast
7MM Coverage
IFIs Epidemiology Segmentation
FAQs
What are the disease risks, burdens, and unmet needs of IFIs? What will be the growth opportunities across the 7MM concerning the patient population with IFIs?
What is the historical and forecasted IFIs patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
To understand the gender-specific radiation-induced esophagitis prevalent cases in varying geographies over the coming years.
The global burden of invasive fungal infections has continued to rise in line with the expanding population at risk. In the United States, the burden is estimated at approximately 110,000 cases in 2024 and is projected to increase during the forecast period (2025–2034).
IFIs primarily affect immunocompromised patients, including those with cancer, HIV/AIDS, organ transplants, critical illness, systemic glucocorticoid use, respiratory conditions, or other severe underlying diseases
The analysis covers major invasive fungal infections such as aspergillosis, candidiasis, histoplasmosis, blastomycosis, coccidioidomycosis, cryptococcosis, mucormycosis, and fusariosis, along with other specified and unspecified IFIs, representing the core spectrum of clinical and market relevance.
Despite confirmed diagnoses, case-fatality rates often exceed 30–50%, with many patients dying before treatment begins, highlighting a critical gap in timely intervention.
DelveInsight's “Invasive Fungal Infections– Epidemiology Forecast – 2034” report delivers an in-depth understanding of Invasive Fungal Infections (IFIs), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Invasive Fungal Infections Understanding
Invasive Fungal Infections Overview
Invasive fungal infections, are severe conditions characterized by the invasion of fungal pathogens into normally sterile sites, including deep tissues and vital organs, often leading to prolonged illness and life-threatening complications. They predominantly affect individuals with weakened immunity, such as patients undergoing chemotherapy, individuals with Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or organ transplant recipients receiving immunosuppressive therapy. Invasive fungal infections are most commonly caused by Candida species (especially Candida albicans, C. glabrata, C. tropicalis, among others), Aspergillus species (especially Aspergillus fumigatus), Cryptococcus species, dimorphic fungi and many more. The fungi involved are usually opportunistic pathogens that are part of the environment or normal human flora but become pathogenic when host defenses are impaired.
Invasive Fungal Infections Diagnosis
The diagnosis of invasive fungal infections relies on a combination of laboratory, imaging, and histopathological approaches, as no single method is sufficiently sensitive or specific on its own. Traditional fungal culture remains the gold standard for species identification and susceptibility testing, though it is time-consuming. Rapid diagnostic tools such as antigen detection assays (e.g., galactomannan and ß-D-glucan) and molecular methods (PCR) are increasingly used for early detection and species-level identification, particularly in immunocompromised patients. Imaging modalities like high-resolution CT and MRI are critical for identifying pulmonary and systemic involvement, while direct microscopy and histopathology provide quick, though less sensitive, evidence of fungal presence in tissue or fluids.
Further details related to country-based variations in diagnosis are provided in the report
Invasive Fungal Infections Epidemiology
The IFIs epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total incident cases of invasive fungal infections, total incident cases of invasive fungal infections by type, total treatment-eligible cases of invasive fungal infections, and total refractory cases of invasive fungal infections, in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
Invasive candidiasis and aspergillosis form the largest group of opportunistic invasive fungal infections, primarily affecting immunocompromised populations, together contributing around 50% of the total burden.
Histoplasmosis and coccidioidomycosis together represent a major portion of the endemic pool. Histoplasmosis cases have been steadily rising.
Approximately, 90% of patients develop resistance to first-line antifungal therapy, necessitating therapy modification. Among these, nearly 30% also develop resistance to second-line agents, forcing switches within drug classes (e.g., azoles) or across classes (e.g., from azoles to echinocandins or polyenes).
Invasive Fungal Infections Report Insights
Invasive Fungal Infections Report Insights
Patient population
Country-wise epidemiology distribution
Invasive Fungal Infections Report Key Strengths
Ten-year Forecast
7MM Coverage
IFIs Epidemiology Segmentation
FAQs
What are the disease risks, burdens, and unmet needs of IFIs? What will be the growth opportunities across the 7MM concerning the patient population with IFIs?
What is the historical and forecasted IFIs patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
To understand the gender-specific radiation-induced esophagitis prevalent cases in varying geographies over the coming years.
Table of Contents
78 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 5. Epidemiology Forecast Methodology
- 6. IFIs Overview at a Glance
- 6.1. Patient Share (%) Distribution of IFIs in 2024
- 6.2. Patient Share (%) Distribution of IFIs in 2034
- 7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Common Types of IFIs
- 7.3. Causes and Risk Factors
- 7.3.1. Risk Factors
- 7.4. Signs and Symptoms
- 7.5. Complications of IFIs
- 7.6. Diagnosis
- 7.6.1. Diagnosis Algorithm
- 7.6.2. Diagnosis Guidelines of IFIs
- 7.6.2.1. American Thoracic Society Practice Guidelines (2019)
- 7.6.2.2. Infectious Diseases Society of America Guidelines (2018)
- 8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale
- 8.3. Total Incident Cases of IFIs in the 7MM
- 8.4. Epidemiology Scenario in the US
- 8.4.1. Total Incident Cases of IFIs in the US
- 8.4.2. Total Incident Cases of IFIs by Type in the US
- 8.4.3. Total Treatment-eligible Cases of IFIs in the US
- 8.4.4. Total Refractory Cases of IFIs in the US
- 8.5. Epidemiology Scenario in EU4 and the UK
- 8.5.1. Total Incident Cases of IFIs in EU4 and the UK
- 8.5.2. Total Incident Cases of IFIs by Type in EU4 and the UK
- 8.5.3. Total Treatment-eligible Cases of IFIs in EU4 and the UK
- 8.5.4. Total Refractory Cases of IFIs in EU4 and the UK
- 8.6. Epidemiology Scenario in Japan
- 8.6.1. Total Incident Cases of IFIs in Japan
- 8.6.2. Total Incident Cases of IFIs by Type in Japan
- 8.6.3. Total Treatment-eligible Cases of IFIs in Japan
- 8.6.4. Total Refractory Cases of IFIs in Japan
- 9. Appendix
- 9.1. Bibliography
- 9.2. Report Methodology
- 10. DelveInsight Capabilities
- 11. Disclaimer
- 12. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
